ProCE Banner Activity

BOREAS: Phase III Trial of Navtemadlin vs Best Available Therapy in Patients With JAK Inhibitor R/R Myelofibrosis

Conference Coverage
Slideset

The phase III BOREAS study of the MDM2 inhibitor navtemadlin in patients with JAK inhibitor relapsed/refractory myelofibrosis showed a greater reduction in spleen volume and total symptom score vs physician’s choice of best available therapy.

Released: December 11, 2024

Expiration: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation